OC
KURA icon

Oppenheimer & Co’s Kura Oncology KURA Stock Holding History

Oppenheimer & Co’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,500
Closed -$110K – 1329
2017
Q1 		$110K Buy
12,500
+1,600
+15% +$11.7K ﹤0.01% 1239
2016
Q4 		$64K Buy
+10,900
New +$58.4K ﹤0.01% 1244

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's KURA Position: Q2 2017 in Review

Oppenheimer & Co sold out of Kura Oncology (KURA) in Q2 2017, closing a stake of 12,500 shares — an estimated $110K sold.

Oppenheimer & Co first reported a position in KURA in Q4 2016 and held it in 2 quarters. The position peaked at $110K in Q1 2017. 44 funds tracked by Wall St. Rank hold KURA as of Q2 2017.

  • Oppenheimer & Co reported no remaining Kura Oncology position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 12,500 Kura Oncology shares in Q2 2017, an estimated $110K.
  • Oppenheimer & Co first reported a position in Kura Oncology in Q4 2016 and held it in 2 quarters.
  • Oppenheimer & Co's Kura Oncology position peaked at $110K in Q1 2017.
  • 44 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2017.

Based on Oppenheimer & Co's 13F filing for Q2 2017, filed 9 Aug 2017.